Clinical trial demonstrates durable long-term survival with CD19 CAR-T therapy in young B-ALL patients, indicating high curative efficacy across disease stages.
Key Points
Infusion of CD19 CAR-T cells achieved morphologic complete remission in all 115 patients, with 96.5% achieving minimal residual disease-negative status within one month.
Over a median 48.4-month follow-up, 4-year leukemia-free survival reached 68.7% and overall survival was 70.7%, showing comparable efficacy across baseline disease states.
Single-arm prospective clinical trial highlights that post-infusion hematopoietic stem cell transplantation improves overall survival primarily for refractory or relapsed patients.